Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
James Chin-Hsin Yang, Myung-Ju Ahn, Kazuhiko Nakagawa, Tomohide Tamura, Helen Barraclough, Sotaro Enatsu, Rebecca Cheng, Mauro Orlando
Cancer Res Treat. 2015;47(3):424-435. Published online 2014 Sep 15 DOI: https://doi.org/10.4143/crt.2013.266
Citations to this article as recorded by 
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng L
The Lancet Respiratory Medicine.2021; 9(3): 305. CrossRef
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
Long-Hua Guo, Ming-Feng Zhang, He-Long Zhang, Jian-Ying Zhou, Xiao-Hong Cai, Yu Long, Qi-Sen Guo, Nong Yang, Jun Zhao, Zhan-Hong Xie, Bo Jiang, Ying Zhu, Yun Fan, Cong-Ying Xie, Yi Hu, Yu Yao, Jun Jia, Xiao-Ling Li, Jiu-Wei Cui, Xi-Zhao Sui, Wen Lin, Ying
Frontiers in Oncology.2020;[Epub] CrossRef
Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status
Xiaoqing Yu, Yun Fan
Medicine.2019; 98(3): e14110. CrossRef
Best Practices in Treatment Selection for Patients with Advanced NSCLC
Mark A. Socinski, Nathan A. Pennell
Cancer Control.2016; 23(4_suppl): 2. CrossRef